Prior high-risk human papillomavirus testing and papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: Results of a retrospective multicenter study

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 2, 2015, Pages 184-188

  Zhao, Chengquan ^a   Li, Zaibo ^a   Nayar, Ritu ^b   Levi, Angelique W ^c   Winkler, Barbara A ^d   Moriarty, Ann T ^e   Barkan, Güliz A ^f   Rao, Jianyu ^g   Miller, Fern ^h   Fan, Fang ⁱ   Zhou, Zhongren ^j   Si, Qiusheng ^k   Fischer, Andrew H ^l   Sturgis, Charles D ^m   Jing, Xin ⁿ   Marshall, Carrie B ^o   Witt, Benjamin L ^p   Birdsong, George G ^q   Crothers, Barbara A ^r  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Mount Kisco Medical Group   (United States)

^e Ameripath Inc   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Metropolitan Pathologists   (United States)

ⁱ UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^m Providence Regional Medical Center   (United States)

ⁿ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^o UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^q EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r WALTER REED ARMY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CARCINOMA; CLINICAL TRIAL; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; RETROSPECTIVE STUDY; RISK; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84921477496     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0028-OA     Document Type: Article

References (21)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
2. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16): 1589-1597.
3. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370(9601):1764-1772.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11(3):249-257.
5. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7): 663-672.
6. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804. doi: 10.1136/bmj.c1804.
7. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168(17):1881-1889.
8. Massad LS, Einstein MH, Huh WK, et al; ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors [published correction appears in J Low Genit Tract Dis. 2013;17(3):367]. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S1-S27.
9. Saslow D, Solomon D, Lawson HW, et al; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-542.
10. Li Z, Austin RM, Guo M, Zhao C. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma. Arch Pathol Lab Med. 2012;136(12):1533-1540.
11. Naryshkin S, Austin RM. Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug, Healthc Patient Saf. 2012;4:167-72. doi:10.2147/DHPS.S37273.
12. Kang WD, Kim CH, Co MK, et al. Comparison of Hybrid Capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. Int J Gynecol Cancer. 2009;19(5):924-928.
13. Zhao C, Li Z, Austin RM. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia. Am J Clin Pathol. 2013;140(1):47-54.
14. Kitchener HC, Almonte M, Gilham C, et al; for the ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1-150, iii-iv.
15. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat. 2009;18(3):94-103.
16. Wu Y, Chen Y, Li L, Yu G, Zhang Y, He Y. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol. 2006;35(3):264-269.
17. Hong D, Ye F, Chen H, et al. Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang Province, China. Int J Gynecol Cancer. 2008;18(1):104-109.
18. Kang WD, Kim CH, Cho MK, et al. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of highgrade cervical lesions. Int J Gynecol Cancer. 2009;19(5):924-928.
19. Boulet GA, Benoy IH, Depuydt CE, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia ≥2 in a liquid-based cytology setting. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2992-2999.
20. Igidbashian S, Schettino MT, Boveri S, et al. Tissue genotyping of 37 in situ and invasive cervical cancer with a concomitant negative HC2 HPV DNA test. J Low Genit Tract Dis. 2014;18(1):87-91.
21. Austin RM, Zhao C. Type 1 and type 2 cervical carcinomas: some cervicalcancers are more difficult to prevent with screening. Cytopathol. 2012;23(1):6-12.